- GlobeNewswire•last month
Neuren’s Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome
MELBOURNE, Australia, March 24, 2017-- Neuren Pharmaceuticals has reported top-line results for its Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. Rett syndrome is a serious and life ...
- Marketwired•2 years ago
We're sorry this is all we were able to find about this topic.
NEU.AX : Summary for NEUREN FPO NZ - Yahoo Finance
Neuren Pharmaceuticals Limited (NEU.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.07 - 0.07|
|52 Week Range||0.04 - 0.09|
|PE Ratio (TTM)||-10.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|